The Jakarta Post
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsRussia offers Indonesia access to Sputnik vaccine
Russian Ambassador to Indonesia Lyudmila Vorobieva said her government had contacted the Health Ministry about the possible distribution and use of the Sputnik V vaccine and was currently waiting for its response.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Set as preferred source
T
he Russian government has officially made an offer to the Indonesian government for the use and further development of a coronavirus vaccine, Sputnik V, which is currently in its Phase III clinical trial.
Russian Ambassador to Indonesia Lyudmila Vorobieva said her government had contacted the Health Ministry about the possible distribution and use of the Sputnik V vaccine and was currently waiting for its response.
"We sent a letter to the ministry on Sept. 17. We're still waiting for a response," Vorobieva said in an interview with The Jakarta Post on Thursday.
The Sputnik V is a vaccine developed by the Gamaleya research institute in coordination with the Russian defense ministry. It is based on a proven vaccine against adenovirus – the common cold.
The vaccine is expected to provide immunity from SARS-CoV-2, the virus that causes COVID-19, for up to two years, according to the Russian health ministry. More than 44,000 people have taken part in the Sputnik V clinical trial.
The platform used for the vaccine was developed by Russian scientists over 20 years and had formed the basis for several vaccines in the past, including those against Ebola. Gamaleya’s vaccine is based on similar technology to the coronavirus vaccine prototype developed by CanSino, a Chinese vaccine-making company.
Earlier, Vorobieva said once the Phase III clinical trial was completed that the first step would be to make the vaccine available in the Indonesian market.
